Planet DDS vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud-native dental practice management including Denticon for DSOs and Apteryx XVWeb for cloud imaging. Irvine CA; founded 2003;
About
Planet DDS is an Irvine, California-based cloud-native dental software company that offers an integrated suite of tools for dental practices, DSOs, and dental imaging, with Denticon as its flagship cloud practice management system and Apteryx XVWeb as its cloud imaging platform. Founded in 2003, Planet DDS built Denticon as one of the first true multi-site, cloud-based dental practice management systems at a time when the market was dominated by legacy on-premise software. Denticon's multi-location architecture allows DSOs and group practices to manage enterprise-level functions—credentialing, reporting, fee schedule management, and patient record sharing across locations—from a centralized cloud platform rather than managing separate on-premise installations at each site.\n\nPlanet DDS has doubled down on the DSO market, where its cloud architecture offers significant operational advantages over legacy systems that require local servers, manual software updates, and location-by-location IT support. The company's acquisition of Apteryx, a dental imaging software business, extended its platform into digital radiography management, allowing practices to manage both clinical workflows and imaging through an integrated cloud environment. Planet DDS also acquired Legwork in 2021, a dental patient communication and marketing platform, adding patient engagement, online scheduling, and reputation management capabilities to its suite.\n\nThe DSO market has been growing rapidly as dental consolidation accelerates, and Planet DDS is positioned to benefit from practices migrating away from Dentrix and Eaglesoft to cloud-native platforms that can scale with multi-location growth. The company integrates with dental imaging sensors, intraoral cameras, and third-party lab management systems. Planet DDS competes with Carestream Dental, Curve Dental, and the Carestream/Apteryx imaging market alongside practice management leaders Dentrix and Eaglesoft, which are owned by Henry Schein.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.